MGRC

There is no doubt that the time is right for a large precision medicine cohort of 1 million people or more due to advances in scientific knowledge, technology and computing, empowerment of patients and the general public, and existing resources of millions of people who already participate in ongoing cohort studies. At a recent workshop, NIH director Dr Francis Collins used examples of early success such as pharmacogenomics tests, new therapeutic targets for common diseases, insights into resilience and healthy aging, and new ways to evaluate m-Health technologies for chronic disease management.